NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
Stage IV Prostate Adenocarcinoma AJCC v7
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma With Neuroendocrine Differentiation
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation

Interventions: Drug: Cediranib
Drug: Olaparib

First Posted Date: 2016-09-09

Last Posted Date: 2025-04-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT02893917

Locations: 🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

and more 13 locations

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related
Recurrent Myelodysplastic Syndrome
Secondary Acute Myeloid Leukemia
Secondary Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome

Interventions: Drug: Decitabine
Biological: Ipilimumab

First Posted Date: 2016-09-07

Last Posted Date: 2025-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT02890329

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 8 locations

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Veliparib

First Posted Date: 2016-09-07

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 123

Registration Number: NCT02890355

Locations: 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 779 locations

Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7
Metastatic Colorectal Carcinoma
Stage IVB Colorectal Cancer AJCC v7

Interventions: Biological: Durvalumab
Radiation: Radiation Therapy
Biological: Tremelimumab

First Posted Date: 2016-09-05

Last Posted Date: 2025-02-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT02888743

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 39 locations

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Phase 3

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
B Acute Lymphoblastic Leukemia
Central Nervous System Leukemia
Testicular Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Clofarabine
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Dasatinib
Drug: Dexamethasone
Drug: Etoposide
Drug: Doxorubicin Hydrochloride
Drug: Hydrocortisone Sodium Succinate
Drug: Leucovorin Calcium
Other: Laboratory Biomarker Analysis
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Thioguanine
Drug: Vincristine Sulfate
Drug: Prednisone
Radiation: Radiation Therapy

First Posted Date: 2016-08-30

Last Posted Date: 2025-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5949

Registration Number: NCT02883049

Locations: 🇺🇸
State University of New York Upstate Medical University, Syracuse, New York, United States
🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Mission Hospital, Asheville, North Carolina, United States

and more 236 locations

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2

Completed

Conditions: Triple-Negative Breast Carcinoma
Invasive Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7

Interventions: Procedure: Biospecimen Collection
Drug: Atezolizumab
Drug: Carboplatin
Procedure: Lumpectomy
Procedure: Mastectomy
Drug: Paclitaxel

First Posted Date: 2016-08-30

Last Posted Date: 2024-07-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 67

Registration Number: NCT02883062

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 11 locations

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Phase 1

Active, not recruiting

Conditions: Refractory Mixed Phenotype Acute Leukemia
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Refractory B Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration and Biopsy
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2016-08-26

Last Posted Date: 2025-02-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT02879695

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

and more 4 locations

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

Phase 1

Terminated

Conditions: Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Breast Ductal Carcinoma In Situ
Early Stage Breast Carcinoma
Anatomic Stage IIB Breast Cancer AJCC v8
Invasive Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Retinoid 9cUAB30
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2016-08-24

Last Posted Date: 2024-06-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT02876640

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 2 locations

Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data

Completed

Conditions: Neoplasm
Outcome Assessment
Health Services Accessibility
Healthcare Disparities

First Posted Date: 2016-08-23

Last Posted Date: 2020-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3217145

Registration Number: NCT02875327

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs

Withdrawn

Conditions: Cancer

First Posted Date: 2016-08-22

Last Posted Date: 2019-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02874053

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy